Note: This variant has not been sufficiently evaluated by a GET-Evidence editor.
To be considered sufficiently evaluated a variant must have both "variant evidence" and "clinical importance" scores filled in.
Please help improve GET-Evidence by evaluating evidence for this variant!
Insufficiently evaluated pathogenic
(The "insufficiently evaluated" qualifier is assigned automatically based on the above evidence and importance scores.)
Summary of published research, and additional commentary
Andreadi C, Cheung LK, Giblett S, Patel B, Jin H, Mercer K, Kamata T, Lee P,
Williams A, McMahon M, Marais R, Pritchard C. The intermediate-activity L597VBRAF
mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling
through the RAF/MEK/ERK pathway. Genes Dev. 2012 Aug 14. [Epub ahead of print]
PubMed PMID: 22892241.